Home

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Recent News

Feb 21, 2018
-Study did not meet its primary endpoint- -Company remains committed to continued development of GWP42006 for autism spectrum disorders and will continue to explore the product’s potential within the field of epilepsy -
Feb 06, 2018
London, UK, Carlsbad, CA, 6 Feb., 2018: GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW’s Chief Executive Officer, will present at the Leerink Partners 7th Annual
Feb 05, 2018
- Epidiolex® (cannabidiol) NDA and MAA applications accepted for review – - NDA PDUFA goal date scheduled for June 27, 2018 - - Conference call today at 4:30 p.m. EST -

Pharmaceutical Development Pipeline

Pharmaceutical Development Pipeline

  • Unpartnered
  • Partnered
  • Pre-Clinic
  • Phase 1
  • Phase 2
  • Phase 3
  • Submit
  • Approved

Epidiolex

Epidiolex
Dravet Syndrome
Submit
Epidiolex
Lennox-Gastaut Syndrome
Submit
Epidiolex
Tuberous Sclerosis
Phase 3
Epidiolex
Infantile Spasms
Phase 2

CBDV (GWP42006)

GWP42006 (CBDV)
Epilepsy
Phase 2
GWP42006 (CBDV)
Autism Spectrum Disorders
Completed Phase 1

Other

GWP42003 (IV)
Neonatal Hypoxic-ischemic Encephalopathy
Phase 1
GWP42002 / GWP42003
Glioblastoma
Completed Phase 2
GWP42003
Schizophrenia
Completed Phase 2

Sativex (U.S.)

Sativex
Ms Spasticity
Phase 3